An FDA advisory panel on Wednesday voted 18-1 that the benefits of Amgen and UCB's monthly injection Evenity (romosozumab) outweigh its risks for the treatment of osteoporosis in postmenopausal women at high risk for fracture. Two members of the panel voted in favour of the sclerostin inhibitor, but proposed approving it for a different indication. The committee also raised concerns of potential cardiovascular risks linked to Evenity, which FDA staff reviewers earlier this week had cited as the main reason for convening the advisory panel meeting.  In 2017, the agency issued a complete response letter to the companies regarding their submission of Evenity, asking them to include efficacy and safety data from the Phase III ARCH study in their filing. In the trial, Evenity was associated with a higher rate of serious cardiovascular adverse events than Merck & Co.'s Fosamax (alendronate). Amgen and UCB resubmitted their filing seeking approval of Evenity to the FDA last July. Still, despite the panel vote backing approval, some panellists again expressed concerns about the drug's cardiovascular risks. "I don't think we've adequately characterised cardiovascular safety," said Pamela Shaw, who voted in favour of approval for Evenity. She added "I don't know the perfect solution, but relying on observational data only post approval, I don't think, will help us answer this reliably. My vote is relying on a high-quality post-marketing study."  Evenity was approved earlier this month for the treatment of osteoporosis in patients at high risk of fracture in Japan, where the therapy is jointly marketed by Astellas.


    George Τrovas

    Laboratory for Research of the Musculoskeletal System (LRMS)
    National and Kapodistrian University of Athens

seractil 1016x130

Management of Chronic Kidney Disease

Association Between Hyponatremia, Osteoporosis and Fracture: a Systematic Review and Meta-analysis

Osteonecrosis Following Short-term, Low-dose Oral Corticosteroids: A Population-based Study of 24 Million Patients

Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults

Hip arthroplasty for elderly hip fracture patients has higher risk of myocardial infarction, mortality compared to ORIF

Simple blood test could be used as tool for early cancer diagnosis

Vitamin C offers no benefits to patients with distal radial fractures.

FRAX underestimates risk of fragility fractures


Roux S. J Clin Endocrinol Metab. 2014;doi: 10.1210/jc.2013-4507.

Smoking increases risk of nonunion following fracture

Comparison of bone scintigraphy uptake patterns may guide nonunion treatment

Higher bone mineral density, smaller bone size found in patients with foot or ankle OA

Fragility fracture care costs EU €37 billion in annual health care costs

Vitamin D in human reproduction

Vitamin D in human reproduction: a narrative review

International Journal of Clinical Practice